Viking Therapeutics (VKTX) Competitors $33.56 -1.42 (-4.06%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$33.20 -0.37 (-1.09%) As of 10/10/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VKTX vs. MDGL, LLY, ASND, VTRS, RDY, ROIV, MRNA, QGEN, BBIO, and ELANShould you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Madrigal Pharmaceuticals (MDGL), Eli Lilly and Company (LLY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Roivant Sciences (ROIV), Moderna (MRNA), Qiagen (QGEN), BridgeBio Pharma (BBIO), and Elanco Animal Health (ELAN). These companies are all part of the "medical" sector. Viking Therapeutics vs. Its Competitors Madrigal Pharmaceuticals Eli Lilly and Company Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories Roivant Sciences Moderna Qiagen BridgeBio Pharma Elanco Animal Health Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment. Which has more risk & volatility, MDGL or VKTX? Madrigal Pharmaceuticals has a beta of -1.02, meaning that its stock price is 202% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Do analysts rate MDGL or VKTX? Madrigal Pharmaceuticals presently has a consensus price target of $525.88, suggesting a potential upside of 22.41%. Viking Therapeutics has a consensus price target of $86.42, suggesting a potential upside of 157.50%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than Madrigal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Madrigal Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73Viking Therapeutics 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.86 Does the media prefer MDGL or VKTX? In the previous week, Viking Therapeutics had 2 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 12 mentions for Viking Therapeutics and 10 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.91 beat Viking Therapeutics' score of 0.68 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, MDGL or VKTX? Viking Therapeutics has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMadrigal Pharmaceuticals$180.13M52.95-$465.89M-$12.85-33.43Viking TherapeuticsN/AN/A-$109.96M-$1.53-21.93 Do insiders & institutionals have more ownership in MDGL or VKTX? 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 21.5% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 4.1% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is MDGL or VKTX more profitable? Viking Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -54.68%. Viking Therapeutics' return on equity of -19.98% beat Madrigal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Madrigal Pharmaceuticals-54.68% -38.38% -27.32% Viking Therapeutics N/A -19.98%-19.38% SummaryViking Therapeutics beats Madrigal Pharmaceuticals on 11 of the 15 factors compared between the two stocks. Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VKTX vs. The Competition Export to ExcelMetricViking TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.77B$3.36B$6.05B$10.29BDividend YieldN/A2.31%5.68%4.75%P/E Ratio-21.9322.1186.0326.56Price / SalesN/A462.56613.26218.67Price / CashN/A46.0237.2660.57Price / Book4.2510.2112.756.52Net Income-$109.96M-$52.40M$3.31B$276.43M7 Day Performance12.92%0.86%0.79%-0.88%1 Month Performance30.38%10.39%6.20%3.55%1 Year Performance-49.03%27.24%80.33%37.91% Viking Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VKTXViking Therapeutics3.919 of 5 stars$33.56-4.1%$86.42+157.5%-46.3%$3.77BN/A-21.9320Analyst ForecastGap UpMDGLMadrigal Pharmaceuticals4.3619 of 5 stars$442.31-0.2%$495.88+12.1%+104.0%$9.82B$180.13M-34.4290News CoverageAnalyst ForecastLLYEli Lilly and Company4.9964 of 5 stars$845.40+0.7%$938.94+11.1%-8.5%$800.13B$53.26B55.2547,000Trending NewsAnalyst ForecastAnalyst RevisionASNDAscendis Pharma A/S3.0976 of 5 stars$210.83+3.3%$244.36+15.9%+60.8%$13.01B$393.54M-40.861,017News CoverageAnalyst ForecastVTRSViatris1.9365 of 5 stars$10.13-0.6%$10.40+2.7%-14.0%$11.81B$14.74B-3.4932,000Analyst ForecastRDYDr. Reddy's Laboratories2.6743 of 5 stars$14.12-0.3%$16.95+20.0%-7.2%$11.79B$334.26B21.3927,811Positive NewsAnalyst ForecastROIVRoivant Sciences3.4157 of 5 stars$16.26+0.6%$19.94+22.6%+35.1%$11.10B$23.23M-23.23860Analyst ForecastInsider TradeMRNAModerna4.2171 of 5 stars$27.54-3.3%$41.81+51.8%-52.8%$10.72B$3.24B-3.665,800Analyst ForecastQGENQiagen4.2959 of 5 stars$46.99+0.4%$49.40+5.1%+11.5%$10.45B$1.98B27.765,765News CoveragePositive NewsAnalyst ForecastBBIOBridgeBio Pharma3.9731 of 5 stars$54.61+3.3%$63.94+17.1%+122.3%$10.44B$221.90M-13.35400Analyst ForecastInsider TradeELANElanco Animal Health2.5408 of 5 stars$20.68+0.2%$18.33-11.3%+36.2%$10.27B$4.44B24.059,000Analyst Upgrade Related Companies and Tools Related Companies Madrigal Pharmaceuticals Competitors Eli Lilly and Company Competitors Ascendis Pharma A/S Competitors Viatris Competitors Dr. Reddy's Laboratories Competitors Roivant Sciences Competitors Moderna Competitors Qiagen Competitors BridgeBio Pharma Competitors Elanco Animal Health Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VKTX) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" E...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
